CLINICAL ROLE -
Erin Hunter is an assistant editor at Pharmacy Times®. She is a proud alumna of the University of Massachusetts. She graduated with degrees in Journalism, Art History, and Environmental Conservation.
Epigenetic Aging Higher Among Breast Cancer Survivors Administered Chemotherapy
Increases in biological aging based on epigenetic measures could be used to inform the future of survivorship care among patients with breast cancer.
2024 DIR Changes May Bring Financial Challenges to Independent Pharmacies
Pharmacies should start to prepare for cash flow challenges when the direct and indirect remuneration changes in 2024.
Understanding Generational Differences Can Help Independent Pharmacies Retain Top Talent
Common assumptions about each generation are often incorrect, according to an expert in generational research.
Community Pharmacies to Advocate for Provider Status
During separate panel discussions at McKesson ideaShare 2023, pharmacists discussed advocacy for pharmacy benefit manager reform and community health worker training.
General Session at McKesson ideaShare 2023 Announces Health Mart Pharmacy of the Year Finalists
McKesson also announced the rollout of the Foster & Thrive program and a new Ohio distribution center during the conference.
Innovation is Necessary to Preserve Independent, Community Pharmacy
Pharmacists can recognize evidence of successful interventions and learn how to integrate them into their own practice.
Pharmacy Technicians With Community Health Worker Training Can Improve the Value of The Pharmacy in Health Care
Community health workers can address issues of health equity to enhance the services of the pharmacy and support a value-based care model.
Expert: The “Sweet Spot” To Expanding the Role of the Pharmacy Technician is Community Health Worker Training
Health Mart is offering a new basic training program with ASHP/ACPE accreditation for pharmacy technicians, along with accredited and non-accredited training.
Golidocitinib May Be Effective for The Most Difficult-To-Treat Subtypes of Peripheral T-cell Lymphoma
Approximately 50% of patients with refractory or relapsed disease achieved complete response following treatment with the Janus kinase 1 (JAK1) inhibitor.
AI Plus Mobile App May Help With Smoking Cessation
More than 4 times as many people who used the app quit smoking compared to a traditional support service.
Multi-Comorbidity, Respiratory Disease Among Highest-Risk Conditions for Pneumococcal Pneumonia
Immunocompromised status still appears to be one of the highest independent risk factors for pneumococcal pneumonia in middle-aged and older adults.
Multivitamin Supplementation May Be Linked With Improved Nutrition in Older Men
Multivitamins were associated with increased cellular oxygen consumption and more optimal blood nutrition biomarkers.
Higher Rates of Insomnia Linked to Older Age, Being a Woman
Current social determinants of health found to have a significant impact on sleep health.
Pediatric Cancer Survivor Shares How ‘Perspective Is Everything’
Pharmacists can help patients live a life of meaning and gratitude after cancer recovery.
Generic Products- June 2023
Products treat ulcerative colitis, urinary tract infection, and psoriatic arthritis.
FDA Approves Supplemental New Drug Application To Expand Mavacamten Label for Obstructive Hypertrophic Cardiomyopathy
VALOR HCM is the second study to show that mavacamten can significantly reduce symptoms of obstructive hypertrophic cardiomyopathy, which includes left ventricular outflow tract.
Genomic Testing is Good But Not Great, According to Expert
Earlier in June, Govindan led an educational session about genomic testing at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Patients Are Less Likely to Buy Generics After Receiving Bad News About Their Health
Negative findings may spur choice of brand-name drugs, despite expense.
Expert: Mirvetuximab Soravtansine-Gynx Does Not Use Up the "Precious Reserves” of Patients with Ovarian Cancer
The folate alpha receptor (FRα) does have a toxicity profile, but unlike other chemotherapies, it does not severely compromise bone marrow and may improve ability to receive more therapies.
Romiplostim Biosimilar Found Non-Inferior to Reference Drug, May Be Effective for Chronic Immune Thrombocytopenia
Despite having a lower cost of development than the innovator, romiplostim biosimilar has comparable efficacy and safety in patients with chronic immune thrombocytopenia.
Social Media May Not Be Sharing Most Accurate Information About Emtricitabine-Tenofovir Alafen as PrEP for HIV
Most tweets accurately communicated which groups of people Descovy for HIV pre-exposure prophylaxis is indicated for, although failed to mention resources about cost.
Smoking Cessation Watch
There are a multitude of benefits to smoking cessation, along with novel resources to make cessation more manageable.
Social Norms Theory-Based Interventions Can Improve Health Care Workers Attitudes Toward Patients With HIV, People Who Inject Drugs
Social norms appear to influence individual behavior more than personal attitudes among people living with HIV.
Most Patients With Early-Stage Classical Hodgkin Lymphoma Achieve Complete Response With Brentuximab Vedotin Combination
Brentuximab vedotin with nivolumab and standard chemotherapy agents produced a nearly 100% overall response rate in patents with early-stage classical Hodgkin lymphoma.
Aflibercept Biosimilar Demonstrates Equivalent Efficacy for Neovascular Age-Related Macular Degeneration
SB15 had a comparable safety, pharmacokinetics, and immunogenicity treatment profile to AFL for age-related macular degeneration.
Investigators Advance PrEPVacc Trial To Evaluate HIV Vaccine Efficacy
The trial will also evaluate the efficacy and safety of a new form of oral pre-exposure prophylaxis for HIV.
The Enhancing Oncology Model Promotes Novel Therapies, May Reduce Cost of Care
Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.
FDA Grants Priority Review to Capivasertib Combination for Locally Advanced, Metastatic Breast Cancer
Capivasertib combined with fulvestrant doubled progression-free survival in patients with recurrent or progressed advanced stage HR-positive HER2-negative breast cancer compared to placebo.
Golidocitinib Shows Efficacy, Durability as Treatment for Aggressive Refractory, Relapsed Peripheral T-Cell Lymphoma
Golidocitinib (DZD4205) is the first Janus kinase 1 inhibitor to be used for this aggressive and rare form of non-Hodgkin lymphoma.
Venetoclax Combinations Have Sustained Long-term Benefits for Relapsed, Refractory Chronic Lymphocytic Leukemia
Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.
2 Clarke Drive Cranbury, NJ 08512